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ABSTRACT
Autologous hematopoietic stem cell transplantation (ASCT) has become standard therapy for primary refractory
(PR REF) or relapsed (REL) Hodgkin’s lymphoma (HL); however, more than half of these patients eventually
relapse and die of their disease. We studied long-term outcomes and evaluated factors influencing progression-free
survival (PFS) in 141 patients with PR REF or REL HL who underwent ASCT between 1985 and 2003. Median age
at ASCT was 30 years (range, 7–60 years); 21 patients had PR REF, and 120 had REL HL. With a median follow-up
of 6.3 years (range, 1–20 years), the probability of PFS at 5 and 10 years was 48% (95% confidence interval [CI],
39%–57%) and 45% (95% CI, 36%–54%) and that of overall survival (OS) was 53% (95% CI, 44%–62%) and 47%
(95% CI, 37%–57%), respectively. Transplant-related mortality at 100 days was 1.4%. Among 45 5- to 20-year
survivors, no late relapses of HL were observed. In multivariate analysis, 3 factors were independently predictive of
poor PFS: chemoresistant disease (relative risk [RR], 2.9; 95% CI, 1.7–5.0), B-symptoms at pretransplantation
relapse (RR, 2.1; 95% CI, 1.3–3.4), and presence of residual disease at the time of transplantation (RR, 2.3; 95% CI,
1.1–4.8). Patients with 0 or 1 of these 3 adverse factors (low-risk disease) had a 5–year PFS of 67% (95% CI,
55%–79%) compared with 37% (95% CI, 22%–52%) in those with 2 factors (intermediate-risk group) and 9% (95%
CI, 0–20%) in those with all 3 factors (high-risk group) (P < .001). The rates of OS at 5 years were 71% (95% CI,
60%–82%), 49% (95% CI, 33%–65%) and 13% (95% CI, 0–27%) in the 3 groups, respectively (P < .001). ASCT
is associated with durable PFS in appropriately selected patients with PR REF or REL HL. Using a simple
prognostic model, we can identify patients with high-risk disease who have predictably unfavorable outcome after
ASCT and require novel therapeutic approaches. A risk-adapted approach should be followed in determining
treatment options for patients with PR REF and REL HL.
© 2006 American Society for Blood and Marrow Transplantation
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Up to 80% of patients with Hodgkin’s lymphoma
HL) are cured with initial radiation therapy, chemo-
herapy, or a combination thereof. However, patients
ith primary refractory (PR REF) or relapsed (REL)
L experience poor outcome from conventional sal-
age treatment regimens [1-4]. High-dose therapy fol-
owed by autologous hematopoietic stem cell trans- ilantation (ASCT) has been frequently used to treat
his group of patients, with survival free of progression
r relapse of 40%–60% at 5 years [5-17].
We report our long-term experience with ASCT in
41 patients with PR REF or REL HL, with follow-up
o 20 years. Along with the analysis of progression-free
urvival (PFS) and overall survival (OS), we describe
atient-, disease-, and treatment-related variables that
nﬂuence long-term outcome and incorporate them into
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N. S. Majhail et al.1066simple prognostic model to identify patients with high-
isk disease. These patients have a predictably unfavor-
ble outcome after ASCT and are candidates for novel
herapeutic approaches.
ATERIALS AND METHODS
atient Characteristics and Eligibility Criteria
A total of 141 consecutive patients underwent ASCT
or PR REF or REL HL between 1985 and 2003 at our
nstitution. Data for patients on this protocol were col-
ected prospectively by the University of Minnesota
lood and Marrow Transplant Database and were
upplemented by individual review, as needed, for
nformation on post-ASCT complications and veriﬁ-
ation of response and disease progression.
Patients were eligible for ASCT if they were  65
ears of age and had an Eastern Cooperative Oncol-
gy Group performance status of 0-2, a life expect-
ncy of  8 weeks, and an absence of major organ
ysfunction not attributable to HL. Criteria for exclu-
ion included the presence of chronic renal insufﬁ-
iency, history of severe before ongoing chronic liver
isease, evidence of active ischemic heart disease or
eft ventricular ejection fraction of  45%, presence
f signiﬁcant obstructive airway disease or diffusion
apacity  50% of predicted, or evidence of human
mmunodeﬁciency virus infection. The treatment pro-
ocol for ASCT was approved by the local institutional
eview board, and all patients gave written informed
onsent before ASCT.
Patients were staged according to the Ann Arbor
taging system [18]. Although positron emission to-
ography (PET) and gallium imaging have also been
sed more recently at our institution, radiologic stag-
ng for this analysis was performed for all patients
sing information obtained from computed tomogra-
hy (CT) scans only. Again, CT scan results alone
ere used to evaluate for response after therapy. Pa-
ients treated initially with radiation therapy had failed
t least 1 salvage combination chemotherapy regimen
efore ASCT. Disease status was assessed immediately
efore ASCT, at days 28 and 100, and then every
months for the ﬁrst year, every 6 months for the
econd and third years, and yearly thereafter.
tem Cell Collection
Bone marrow was the stem cell source for 72
atients (51%), whereas 69 patients (49%) received
eripheral blood–derived stem cells. Beginning in
994, all patients underwent 1 cycle of priming che-
otherapy with either granulocyte colony–stimulating
actor (G-CSF) or granulocytes macrophage colony–
timulating factor (GM-CSF) before bone marrow or
eripheral blood stem cell collection. Patients received
-CSF 250 g/m2/day subcutaneously on days 1–7 Aith apheresis on days 6–8, followed by priming
hemotherapy consisting of intravenous cyclophos-
hamide (4 g/m2 on day 1), cytarabine (1 g/m2 twice
aily on day 1), mitoxantrone (8 mg/m2/day on days
and 2) and dexamethasone (20 mg/m2 twice daily
n days 1 and 2), followed by G-CSF beginning on
ay 4 and continuing until completion of apheresis.
atients who did not achieve the minimum target of
 106 CD34 cells/kg were eligible to undergo
M-CSF–mobilized bone marrow harvest if the bone
arrow was of adequate cellularity and free of disease.
onditioning Regimen and Supportive Measures
The CBV conditioning regimen consisted of in-
ravenous cyclophosphamide 1.5 g/m2 for 4 days (days
6 to3), BCNU 300 mg/m2 for 1 day (day6), and
toposide 150 mg/m2 twice daily for 3 days (days 6
o4). Beginning in 1989, involved ﬁeld radiotherapy
as given to sites of residual nodal disease ( 2 cm)
ersisting at day 28 to achieve clinical remission (41
atients). From 1994 onward, patients received G-CSF
upport from day 0 until recovery of absolute neutrophil
ount (ANC) to  2.5  109/L for 3 consecutive days
67 patients).
tudy Definitions
PFS was deﬁned as survival in complete remission
CR) or stable partial remission (PR); recurrence after
chieving CR or an increase in existing or new disease
ites after achieving stable PR was considered disease
rogression. CR was deﬁned as complete absence of
isease on clinical, radiologic, and, if indicated, patho-
ogical (bone marrow or lymph node biopsy) evalua-
ion. PR was deﬁned as  50% reduction in sites of
nown disease. Failure to achieve PR was character-
zed as persistent disease. A patient was classiﬁed as
aving primary refractory (PR REF) disease if he or
he failed to achieve an initial remission with ﬁrst-line
hemotherapy or had disease progression within 3
onths of completion of ﬁrst-line chemotherapy. Pa-
ients achieving at least PR with salvage therapy were
onsidered to have “chemosensitive disease,” whereas
hose who failed to achieve PR were classiﬁed as hav-
ng “chemoresistant disease.” In selected situations,
atients proceeded to ASCT on disease relapse with-
ut undergoing any salvage therapy; these patients
ere categorized as “untreated relapse.” Treatment-
elated mortality (TRM) was deﬁned as death not
ttributable to progression of HL within 100 days of
SCT.
tatistical Analysis
Sex and age at ASCT were patient-related vari-
bles analyzed for PFS and OS. Disease-related prog-
ostic variables at initial diagnosis included histology,
nn Arbor stage, presence of B-symptoms, disease
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Autologous Transplantation in Hodgkin’s Lymphoma 1067ulk ( 10 cm), presence of extranodal or mediastinal
isease, presence of bone marrow involvement, num-
er of regimens needed to achieve ﬁrst CR, and du-
ation of ﬁrst CR. Disease- and treatment-related
rognostic factors at transplantation included number
f previous chemotherapy regimens; time from initial
iagnosis to ASCT; ASCT for PR REF versus REL
isease; year of ASCT; Ann Arbor stage at pre-ASCT
elapse; presence of B symptoms at pre-ASCT relapse;
isease bulk at pre-ASCT relapse ( 5 cm); presence
f extranodal, bone marrow, or pulmonary disease at
re-ASCT relapse; chemoresponsiveness at ASCT;
resence of residual disease at ASCT; stem cell source;
nd use of radiation therapy after ASCT. All of these
ariables were considered in a multivariate model to
dentify factors inﬂuencing PFS and OS.
Probabilities of PFS and OS were calculated using
he Kaplan-Meier method, with 95% conﬁdence in-
ervals (CIs) derived from the standard errors [19].
urvival was calculated from the date of ASCT. Pa-
ients were censored at the time of last follow-up for
alculating PFS and OS. Survival curves in univariate
nalysis were compared using the log-rank test. Mul-
ivariate analysis to identify predictors of survival was
erformed using a forward-stepwise Cox proportional
azards model [20]. All P values reported are 2-sided,
nd P values  .05 were considered statistically sig-
iﬁcant. Data analysis was performed using the SAS
oftware, version 8.0 (SAS Institute, Cary, NC).
ESULTS
atient Characteristics
Patient and disease characteristics of the 141 pa-
ients at the time of initial diagnosis of HL and at the
ime of ASCT are summarized in Table 1. The me-
ian age at initial diagnosis was 27 years (range, 6–57
ears), and 59% of the patients were male. Nodular
clerosis HL was the most common histology (87%).
dverse prognostic features at initial diagnosis in-
luded the presence of B-symptoms (61%), bulky dis-
ase (26%), and extranodal disease (20%). Most pa-
ients (n  130; 92%) received chemotherapy with or
ithout radiation therapy as initial treatment; only 11
atients (8%) were treated with radiation therapy
lone. Commonly used ﬁrst-line chemotherapy regi-
ens included mechlorethamine, vincristine, procar-
azine and prednisone (MOPP) or a derivative regi-
en (n  34), adriamycin, bleomycin, vinblastine and
acarbazine (ABVD) (n  54), and an alternating or
ybrid MOPP-ABV(D) regimen (n  36). In patients
chieving an initial CR, the median duration of remis-
ion was 10 months (range, 2–120 months); of these,
4 patients (60%) relapsed within 1 year.
The median age at ASCT was 30 years (range,
–60 years). Twenty-one patients (15%) had PR REF,able 1. Patient and Disease Characteristics (n  141)
Characteristic
No. of
Patients (%)
t initial diagnosis
Age
Median 27 years
Range 6–57 years
Sex
Male 83 59
Female 58 41
Histology
Nodular sclerosis 122 87
Mixed cellularity 11 8
Lymphocyte predominant 6 4
Lymphocyte depleted 2 1
Ann Arbor stage
I 5 3
II 56 40
III 52 37
IV 28 20
B symptoms 86 61
Bulky disease (> 10 cm) 37 26
Mediastinal disease 97 69
Bone marrow involvement 17 12
t ASCT
Age
Median 30 years
Range 7–60 years
Therapy regimens before ASCT
< 2 86 61
> 2 55 39
Time from diagnosis to ASCT
< 2 years 71 50
> 2 years 70 50
Duration of CR1
< 12 months 84 60
> 12 months 57 40
Year of ASCT
1985–1993 74 52
1994–2003 67 48
Disease status*
Primary refractory 21 15
Relapse 120 85
Ann Arbor stage*
I 9 6
II 57 40
III 25 18
IV 50 36
B symptoms* 61 43
Bulky disease (> 5 cm)* 52 37
> 2 sites of extranodal disease* 6 4
Bone marrow involvement* 27 19
Pulmonary involvement* 20 14
Chemoresponsiveness at ASCT
Sensitive 96 68
Resistant 34 24
Untreated 11 8
Disease status at ASCT
Disease free 34 24
Residual disease present 107 76
Stem cell source
Peripheral blood 69 49
Bone marrow 72 51
Adjuvant radiotherapy post-ASCT 71 50
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N. S. Majhail et al.1068nd 120 patients (85%) had REL HL; ASCT was
erformed in 83 patients (59%) for ﬁrst relapse, in 19
13%) for second relapse, and in 18 (13%) for third or
ubsequent relapse. ASCT was performed at a median
f 25 months (range, 7-220 months) from the initial
iagnosis of HL. At the time of pre-ASCT relapse,
3% of the patients had B symptoms and 36% had at
east 1 site of extranodal disease, including 19% with
one marrow involvement and 14% with pulmonary
nvolvement. Although 92% of the patients received
alvage chemotherapy, only 34 patients (24%) attained
R before ASCT. Overall, 96 patients (68%) had
hemosensitive disease, 34 (24%) had chemoresistant
isease, and 11 (8%) had untreated relapse at the time
f ASCT. Most of the patients with chemoresistant
isease (28/34) underwent transplantation before
994. Forty-one patients (29%) received radiation
herapy post-ASCT.
esponse to ASCT and Survival
At the day 100 evaluation, 122 patients (86%)
ad achieved a response to ASCT, including 110 pa-
ients (78%) with CR and 12 (8%) with PR. Of the
07 patients with pretransplantation residual disease,
6 (71%) achieved CR after ASCT.
The median follow-up of surviving patients was
.3 years (range, 1–20 years); 26 survived beyond 10
ears. The probability of PFS was 48% (95% CI,
9%–57%) at 5 years and 45% (95% CI, 36%–54%)
t 10 years; that of OS was 53% (95% CI, 44%–62%)
t 5 years and 47% (95% CI, 37%–57%) at 10 years
Figure 1). Overall, 65 (46%) patients have died, with
rogressive HL the primary cause of death in 50 of
hese patients.
The outcomes of patients with PR REF and REL
isease were comparable. The 10-year PFS was 45%
95% CI, 23%–68%) for PR REF and 45% (95% CI,
5%–55%) for REL HL, and the 10–year OS was
igure 1. Probability of OS and PFS after ASCT for primary
tefractory or relapsed HL.8% (95% CI; 25%–71%) for PR REF and 47%
95% CI, 36%–58%) for REL HL.
A total of 63 patients had progression of HL at a
edian of 6 months (range,  1 month–5 years) after
SCT. Of these patients with progressive disease, 57
91%) exhibited evidence of disease progression within 2
ears of ASCT; 6 later relapses occurred between 2 and
years after ASCT. Forty-ﬁve patients continued in CR
t 5 years followup post-ASCT; all remained disease-free
uring additional follow-up periods ranging from 5 to
0 years. Overall, the cumulative incidence of disease
rogression at 2 years was 39% (95% CI, 31%–47%).
atients with chemorefractory disease had a 2-year
robability of disease progression of 82% (95% CI,
9%–95%), compared with only 24% (95% CI, 15%–
3%) in those with chemosensitive disease (P  .001)
Figure 2).
rognostic Factors
Variables signiﬁcantly affecting OS and PFS on
nivariate and multivariate analysis are listed in
ables 2 and 3. In multivariate analysis, factors inde-
endently predictive of favorable OS were 2 or fewer
revious chemotherapy regimens (P  .02) and che-
osensitive disease at the time of ASCT (P  .01).
bsence of B-symptoms at pretransplantation re-
apse (P  .01), transplantation in CR (P  .03), and
hemosensitive disease at the time of ASCT (P 
01) were independent signiﬁcant predictors for im-
roved PFS.
Because all 3 variables identiﬁed as being predic-
ive of PFS on multivariate analysis had nearly iden-
ical estimated coefﬁcients, we incorporated them into
prognostic model with no loss of relevant informa-
ion. The 5-year PFS was 67% (95% CI, 55%–79%)
n patients with none or 1 of these 3 adverse prognos-
igure 2. Cumulative incidence of disease progression stratiﬁed by
hemoresponsiveness after ASCT for primary refractory or relapsed
odgkin’s lymphoma.ic factors (low-risk group; n  76), compared with
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Autologous Transplantation in Hodgkin’s Lymphoma 10697% (95% CI, 22%–52%) in those with 2 factors
intermediate-risk group; n  42) and 9% (95% CI,
-20%) in those with all 3 factors (high-risk group;
 23) (P  .001) (Figure 3). Notably, all patients
ith chemorefractory disease fell into either the in-
ermediate-risk or the high-risk group. This model
as also predictive of OS; OS at 5 years was 71%
95% CI, 60%–82%) for the low-risk group, 49%
95% CI, 33%–65%) for the intermediate-risk group,
able 3. Factors Signiﬁcantly Affecting OS and PFS in
ultivariate Analysis
Prognostic Factor
Relative
Risk 95% CI P
S
Total number of previous regimens
< 2 1.0 .02
> 2 1.8 1.1–3.1
Chemoresponsiveness at ASCT
Sensitive 1.0 <.01
Resistant 5.3 3.1–9.1
FS
B-symptoms at pre-ASCT relapse
Absent 1.0 <.01
Present 2.1 1.3–3.4
Chemoresponsiveness at ASCT
Sensitive 1.0 <.01
Resistant 2.9 1.7–5.0
Disease status at ASCT
Disease free 1.0 .03
able 2. Factors Affecting OS and PFS in Univariate Analysis
Variable n 5-ye
ear of ASCT
1985–1993 74 4
1994–2003 67 6
otal number of previous regimens
< 2 86 5
> 2 55 4
uration of CR1
> 12 months 57 6
< 12 months* 84 4
ulk at pre-ASCT relapse
< 5 cm 89 6
> 5 cm 52 3
xtranodal disease at pre-ASCT relapse
Absent 91 6
Present 50 3
-symptoms at pre-ASCT relapse
Absent 80 5
Present 61 4
hemoresponsiveness at ASCT
Sensitive 96 6
Resistant 34
Untreated 11 4
isease status at ASCT
Disease-free 34 6
Residual disease present 107 4
Includes patients with PR REF disease.t
Residual disease present 2.3 1.1–4.8nd 13% (95% CI, 0–27%) for the high-risk group
P  .001).
For the 96 patients with chemosensitive disease,
he presence or absence of B-symptoms at pretrans-
lantation relapse was the only variable independently
redictive of PFS. The 10-year rate of PFS was 67%
95% CI, 53%–81%) in patients with no B-symp-
oms, compared with 45% (95% CI, 26%–64%) in
hose presenting with B-symptoms at the time of pre-
SCT relapse (P  .03). For the 34 patients with
hemoresistant HL, the year of transplantation was
he only factor signiﬁcantly associated with PFS; PFS
t 5 years was 4% (95% CI, 0–12%) for patients
ndergoing transplantation before 1993 versus 33%
95% CI, 2%–64%) for those receiving ASCT in and
fter 1994 (P  .01).
omplications of ASCT
TRM within 100-days post-ASCT was 1.4% (2
atients, 1 each dying of sepsis and hepatic veno-
cclusive disease). Eight patients (6%) developed my-
lodysplastic syndrome (MDS)/acute myelogenous
eukemia (AML) at a median of 2.6 years (range, 10
onths–7 years) after ASCT. All 8 patients had re-
eived alkylator-based chemotherapy before ASCT.
ive patients were diagnosed with malignancies other
han MDS/AML, including 1 patient each with ade-
ocarcinoma of the colon (at 2 years), basal cell car-
inoma of the skin (at 4.3 years), carcinoma in situ of
(95% CI) P 5-year PFS (95% CI) P
54%) .05 34% (23–45%) .05
79%) 50% (35–65%)
71%) .04 48% (36–60%) .06
55%) 31% (18–44%)
75%) .04 46% (14–60%) .10
56%) 38% (27–49%)
73%) <.01 51% (40–62%) <.01
46%) 24% (12–36%)
72%) .02 47% (36–58%) .05
49%) 30% (16–44%)
71%) .02 51% (39–63%) <.01
54%) 28% (16–40%)
80%) <.01 54% (43–65%) <.01
0%) 7% (0–16%)
75%) 36% (7–65%)
83%) .09 62% (42–82%) <.01
58%) 34% (25–43%)ar OS
3% (32–
5% (50–
8% (46–
1% (27–
0% (45–
4% (32–
2% (50–
1% (16–
1% (49–
4% (19–
9% (46–
1% (27–
9% (58–
9% (0–2
5% (16–
3% (42–
7% (37–he cervix (at 3.6 years), diffuse large B-cell lymphoma
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N. S. Majhail et al.1070at 8.3 years), and mantle cell lymphoma (at 3.7 years).
he cumulative incidence of MDS/AML at 10 years
as 10% (95% CI, 3%–17%), and that of any second
alignancy was 16% (95% CI, 7%–25%). Age at
SCT, use of radiotherapy before or after ASCT, and
he number of previous chemotherapy regimens were
ot associated with the risk of either MDS/AML or
ny second malignancy.
ISCUSSION
We report our large prospective series of ASCT
or PR REF or REL HL with extended long-term
ollow-up. All patients received the same conditioning
egimen before ASCT and underwent the same fol-
ow-up and staging procedures both before and after
ransplantation. Our results are comparable to those
igure 3. Probability of PFS (A) and OS (B) based on a prognostic
odel using low-risk (0 or 1 adverse prognostic factors), interme-
iate-risk (2 adverse prognostic factors), or high-risk (3 adverse
rognostic factors) groups. The 3 adverse prognostic factors incor-
orated into the model included B-symptoms at pre-ASCT relapse,
hemoresponsiveness pretransplantation relapse, and complete re-
ission at the time of ASCT.eported in the literature and suggest that high-dose ohemotherapy followed by ASCT can lead to long-
erm and, most importantly, durable PFS in selected
atients. TRM was low. Many patients in our cohort
ad poor-risk features, including B-symptoms both at
iagnosis and at pretransplantation relapse, short du-
ation of ﬁrst remission, extensive previous therapy,
elatively short time to transplantation from diagnosis,
nd presence of residual disease at the time of trans-
lantation. Nonetheless, we found a 10-year PFS of
5% and a 10-year OS of 47%. Most relapses (91%)
ccurred within 2 years, and all relapses occurred
ithin 5 years of transplantation. Although some pub-
ished series have described frequent relapses beyond
years after transplantation [9,15], late relapses are
are, and the great majority of appropriately chosen
atients can be expected to achieve durable long-term
emission with ASCT.
Chemoresponsiveness before transplantation has
een reported to be a consistently strong prognostic
actor in most published series and provides the main
election criterion for ASCT [5,7,8,12]. We have con-
rmed chemoresponsiveness as an independent pre-
ictor of both PFS and OS on multivariate analysis.
e tried to identify favorable prognostic factors
ithin the chemosensitive and chemoresistant disease
roups. Patients without B-symptoms at pretransplan-
ation relapse had a better outcome within the che-
osensitive group. Within the chemoresistant group,
he only factor predictive of better post-ASCT PFS
as the year of transplantation. Most of our patients
ith chemoresistant disease underwent transplanta-
ion before 1994. Our institutional protocol for ASCT
or HL was modiﬁed in 1994 to exclude patients with
isease unresponsive to salvage chemotherapy. Al-
hough classiﬁed as having chemoresistant disease, all
atients from this subcohort undergoing ASCT after
994 exhibited at least a minor response to salvage
hemotherapy compared with the earlier patients,
ho typically demonstrated no response or worsening
f disease. Overall, patients with chemoresistant ad-
anced HL need a more aggressive therapeutic ap-
roach, and ASCT in its current form is an inadequate
reatment option for these patients.
PET imaging is more sensitive than and superior
o CT scans for radiologic staging of HL and for
etecting early relapse and posttransplantation resid-
al disease [21-23]. Positive pretransplantation 18-
ourodeoxyglucose PET has also been identiﬁed as an
dverse prognostic factor for relapse after ASCT
24,25]. Because most of the patients in our cohort did
ot undergo PET staging, we could only use infor-
ation obtained from CT scans for assessing disease
tage and response to therapy. Radiologic staging was
imited to CT scans to follow uniform staging and
esponse criteria for all patients undergoing transplan-
ation during this extended period and to prevent
verstaging of more recent patients undergoing PET
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Autologous Transplantation in Hodgkin’s Lymphoma 1071maging along with CT scans. PET imaging might be
ble to deﬁne chemoresponsive disease more accu-
ately and identify patients most suitable for ASCT.
owever, patients with PET-only positive disease
re-ASCT or post-ASCT usually pose a therapeutic
hallenge; the role of PET in the peritransplantation
anagement of HL is currently being investigated.
Improvements in transplantation techniques and
upportive care have made ASCT a safe procedure
ith very low transplantation-related morbidity and
ortality; the 100-day TRM in our series was 1.4%.
n addition, because many patients undergoing ASCT
or advanced HL will achieve long-term remission,
he focus has now shifted toward late complications,
ncluding the risk of second malignancies. The wor-
isome incidence of MDS/AML and second malig-
ancy in our study is comparable to that reported in
he literature [5,6,9,15,26,27]. In a recent analysis of
732 consecutive patients treated for HL, Forrest
t al. [28] observed a 9% cumulative incidence of
eveloping a second malignancy at 15 years. The in-
idence did not differ signiﬁcantly between patients
ho received conventional chemotherapy alone and
hose who underwent ASCT. Sureda et al. [9] re-
orted a 4.3% 5-year cumulative incidence of second
ancers in 494 patients undergoing ASCT for ad-
anced HL; use of radiation therapy pretransplanta-
ion, use of total-body irradiation–containing regi-
ens, and age  40 years at transplantation were
ndependently predictive for the development of sec-
nd malignancies on multivariate analysis. We did not
nd any association between age, use of radiation
herapy, or the amount of previous chemotherapy
ith the risk of developing MDS/AML or second
alignancy after ASCT. However, any analysis of risk
actors for second malignancy in this setting must be
nterpreted with caution, because of the small number
f events.
Most posttransplantation relapses occurred early,
nd most affected patients succumbed to their under-
ying lymphoma soon thereafter despite the use of
arious posttransplantation salvage chemotherapy
egimens. Recognizing patients with advanced HL
ho will not beneﬁt from the current approach to
SCT early in the course of the disease remains a
hallenge. We have identiﬁed B-symptoms at pre-
ransplantation relapse, chemoresponsiveness before
ransplantation, and remission status at transplanta-
ion as independent predictors of long-term disease-
ree survival. Other factors reportedly associated with
oor outcome after ASCT include advanced age, ele-
ated low-density lipoprotein levels and poor perfor-
ance status at time of transplantation, presence of
xtranodal or bulky disease before transplantation,
nd short duration of ﬁrst CR or extensive previous
hemotherapy [5-10,12,14,26,27,29,30]. The presence
r absence of these prognostic variables should beonsidered when making individual patient decisions
egarding ASCT for advanced HL. In our analysis,
atients at lowest risk of relapse after ASCT were
hose with none or 1 of the 3 adverse prognostic
actors; almost all patients with all 3 adverse factors
xperienced relapse within 2 years of transplantation.
his prognostic model is applicable for predicting
oth PFS and OS.
Similar models have been proposed by other in-
estigators. Moskowitz et al. [8], in their series of 65
atients followed for a median of 43 months, observed
xtranodal disease, duration of ﬁrst CR, and B-symp-
oms to be predictive of event-free survival after
SCT for HL and proposed a prognostic model in-
orporating these 3 variables. Another prognostic
odel was suggested by Wheeler et al. [7] based on
heir analysis of 102 patients with a median follow-up
uration of 4 years; their model includes chemore-
ponsiveness, number of extranodal disease sites, and
erformance status.
That the present paradigm of broad application of
SCT for PR REF and REL HL can be improved by
more risk-adapted approach is becoming increas-
ngly clear. Prognostic models, similar to the one
roposed by our group and by others, need to be
xplored further and validated so that patients at very
igh risk for relapse after ASCT can be identiﬁed
efore ASCT and enrolled in clinical trials investigat-
ng more aggressive and novel therapies.
In summary, there is a need for a risk-adapted
pproach to determining appropriate therapeutic
trategies for patients with PR REF and REL HL. We
uggest that ASCT, in its current form, should not be
ffered to patients at very high risk for posttransplan-
ation relapse, and they should instead be encouraged
o participate in clinical trials investigating novel ther-
pies, including innovative ASCT techniques and al-
ogeneic hematopoietic stem cell transplantation.
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